QURE CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds uniQure (QURE) Investors of Securities Class Action Deadline on April 13, 2026

Core Viewpoint - The article discusses a class action lawsuit against uniQure N.V. for alleged violations of federal securities laws, with a deadline for investors to seek lead plaintiff status by April 13, 2026 [1]. Group 1: Allegations Against uniQure - The complaint alleges that uniQure and its executives made false and misleading statements regarding the approval status of the Pivotal Study design by the FDA [1]. - It is claimed that the company downplayed the likelihood of needing to delay its Biologics License Application (BLA) timeline due to the necessity of additional studies [1]. - The lawsuit asserts that the statements made by the defendants regarding the company's business and prospects lacked a reasonable basis [1]. Group 2: Impact of FDA Disclosure - On November 3, 2025, uniQure disclosed that the FDA no longer agreed that data from the Phase I/II AMT-130 studies would be adequate for BLA submission, leading to a significant drop in share price [1]. - Following this disclosure, uniQure's share price fell by $33.40, or over 49%, from $67.69 on October 31, 2025, to $34.29 on November 3, 2025 [1]. Group 3: Class Action Participation - The lead plaintiff in the class action will be the investor with the largest financial interest who is typical of class members and oversees the litigation [1]. - Any member of the putative class can move to serve as lead plaintiff or choose to remain an absent class member without affecting their ability to share in any recovery [1].